Expansion adds 100,000-square-feet and up to 350 Employees to Fort Worth Headquarters in the next few years

Fort Worth, TX — Tuesday, May 10, 2016 — Fort Worth-based Galderma Laboratories, L.P., celebrated a major milestone with the topping out of its new Research and Development center. The expansion to its current North American headquarters will be completed in first quarter 2017 and will add 100,000- square- feet to the current 170,000-square-foot campus. The $22 million R&D, training and office building will also add up to 350 new positions to the company over the next few years, increasing home office employees to more than 600. Galderma is located at 14501 N. Freeway.

Born in Texas in 1961, Galderma is a global leader solely focused on dermatology and skin health with over 6,000 employees worldwide and a presence in 100 countries. The company provides an extensive portfolio of prescription, self-medication, and aesthetic and corrective medical solutions to patients, consumers and health care practitioners, including Cetaphil®, the iconic brand of cleansers and moisturizers born in San Antonio in 1947.

Under the umbrella of Nestlé Skin Health, Galderma has lately been experiencing a tremendous amount of growth following the launch of nine products in the past 20 months, including Cetaphil® Men and Baby lines; prescription Soolantra® (ivermectin) Cream, 1%; Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%; and the aesthetic treatments, Restylane® Silk and Restylane® Lyft.

“This expansion shows Galderma’s commitment to both skin health innovation and the Fort Worth community,” said Miles Harrison, General Manager and President of Galderma North America. “It’s a game-changer in that it will allow us to double the number of staff at our North American headquarters, increase our talent and concentrate on our one and only focus: providing for skin health needs at every stage of life.”

“We are proud that Galderma chose to invest in R&D and expand its Fort Worth footprint,” said Mayor Betsy Price. “We appreciate the company’s commitment to creating hundreds of new jobs here in Fort Worth and look forward to mutual continued growth and success in our city.”

About Galderma

Dating back to 1961, Galderma is now present in 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

Strategic brands in the U.S. include Epiduo®, Oracea®, Clobex®, Differin®, Mirvaso®, MetroGel®, Soolantra®, Vectical®, Tri-Luma®, Cetaphil®, Benzac® Acne Solutions, Restylane®, Restylane® Silk, Restylane® Lyft, Dysport® and Sculptra® Aesthetic.

For more information, please visit www.galderma.com and www.galdermausa.com.

The Dysport trademark is used under license.

All trademarks are the property of their respective owners.

Contacts:

Virginie Naigeon,

Communications Director,

Galderma North America

virginie.naigeon@galderma.com